GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts

GeoVax Labs, Inc. (NASDAQ:GOVX) has received a consensus recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $14.20.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a research note on Thursday, April 10th.

Hedge Funds Weigh In On GeoVax Labs

Institutional investors have recently made changes to their positions in the stock. Northern Trust Corp acquired a new stake in shares of GeoVax Labs in the 4th quarter valued at about $29,000. Virtu Financial LLC acquired a new stake in GeoVax Labs in the third quarter valued at approximately $97,000. Citadel Advisors LLC bought a new stake in shares of GeoVax Labs during the fourth quarter valued at approximately $104,000. Finally, Geode Capital Management LLC raised its position in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the period. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Stock Performance

NASDAQ:GOVX opened at $1.07 on Thursday. GeoVax Labs has a 52 week low of $0.88 and a 52 week high of $11.18. The firm’s fifty day moving average is $1.42 and its 200-day moving average is $1.98. The firm has a market cap of $14.81 million, a P/E ratio of -0.19 and a beta of 3.70.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.38 million. As a group, sell-side analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.